Adragos Hub

For pharma and biotech companies, selecting a sterile manufacturing partner is about more than equipment or capacity alone. It is about choosing a site that can combine reliable PFS manufacturing, sterile vial production, quality systems and operational support in a way that enables […]

Munich, April 1, 2026 – Adragos Pharma, a global contract development and manufacturing organization (CDMO), today announced that it completed the acquisition of a commercial-scale sterile fill-finish facility in Maisons-Alfort, France, from Sanofi. The Maisons-Alfort site is one of Europe’s largest manufacturing facilities for sterile […]

Why small-molecule development risk is often discovered too late  Small-molecule development does not usually fail because teams lack effort. It fails because risk is discovered too late. The cost then appears as rework, delayed approvals, or supply plans that collapse […]

In small-molecule development, risk rarely appears as a single obvious event. It usually emerges through an atypical analytical result that cannot be defended, a stability trend that forces reformulation, a tech transfer that loses process intent, or an HPAPI handling gap that […]

Optimizing fill–finish for biologics begins at a point where resources are constrained, knowledge is incomplete, and regulatory scrutiny is intense. The central task is to convert a promising molecule into a phase-appropriate, manufacturable dosage form that is safe, stable, and clinically usable—often […]

In the high-stakes world of small-molecule development, the transition from pre-clinical “garage-style” synthesis to a scalable, GMP-ready clinical candidate is where most asset valuations either soar or plummet. For small and mid-sized pharma companies, this is not just a technical hurdle, it is a […]